An In Vivo Inflammatory Loop Potentiates KRAS Blockade

An In Vivo Inflammatory Loop Potentiates KRAS Blockade

KRAS (KRAS proto-oncogene, GTPase) inhibitors perform less well than other targeted drugs in vitro and fail clinical trials. To investigate a possible reason for this, we treated human and murine tumor cells with KRAS inhibitors deltarasin (targeting phosphodiesterase-δ), cysmethynil (targeting isop...

Full description

Bibliographic Details
Main Authors: Kristina A. M. Arendt, Giannoula Ntaliarda, Vasileios Armenis, Danai Kati, Christin Henning, Georgia A. Giotopoulou, Mario A. A. Pepe, Laura V. Klotz, Anne-Sophie Lamort, Rudolf A. Hatz, Sebastian Kobold, Andrea C. Schamberger, Georgios T. Stathopoulos
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Biomedicines
Subjects:
deltarasin
IL-1β
IL1R1
KRAS
KRAS mutation
KRAS<sup>G12C</sup>
Online Access:https://www.mdpi.com/2227-9059/10/3/592

Internet

https://www.mdpi.com/2227-9059/10/3/592

Similar Items